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Abstract 
 
Carbapenemases are being increasingly reported in Enterobacteriaceae including Klebsiella pneumoniae causing 
considerable increases in morbidity and mortality with limited therapeutic options. Issues related to difficulties associated with 
pathogen identification and infection control have been identified as major obstacles to the control of these multi-drug resistant 
organisms. Identification of this enzyme in organisms not previously found to harbor them has added to the already existing 
challenge in the control of this growing problem. The case of a 60 year-old Saudi lady with diabetes, hypertension, pituitary 
adenoma, hypothyroidism, and obstructive sleep apnea who was admitted in our intensive care unit following a cardiac arrest is 
hereby presented. During the course of her treatment she acquired various infections that led to her exposure to antimicrobials 
from almost all classes at various times; including bacteremia due to a pan-drug resistant Klebsiella pneumoniae and multi-drug 
resistant Acinetobacter baumannii. She was successfully treated with a combination of colistin and amikacin. This case highlights 
the resurgence of colistin in clinical practice and also calls for the need to expand our antibiogram to include antibiotics not 
conventionally reported, especially in areas where drug resistance is a growing problem. Improving susceptibility detection 
methods for Klebsiella pneumoniae and hand hygiene could prove effective in reducing nosocomial infections. Involvement of 
clinical pharmacists in antimicrobial stewardship could reduce the development of antimicrobial drug resistance.  
 
Key words: Klebsiella pneumoniae, pan-drug resistance, infection, intensive care unit. 
 
 
Introduction 
 
The rising incidence of carbapenemase-producing Klebsiella pneumoniae has caused considerable challenge to the 
infectious diseases (ID) physician due to lack of therapeutic options. This rise has led to significant morbidity and mortality (Patel 
et al., 2008). Other infectious bacteria producing enzymes identical to the Klebsiella pneumoniae carbapenemases (KPCs) are also 
emerging rapidly as a cause of multidrug-resistant infections worldwide (Quale J, 2008). Carbapenemases other than KPC have 
also been associated with Klebsiella pneumoniae. These associations have been reported from many geographic zones in both 
metallo- (IMP, VIM and NDM) and non-metallo (KPC and OXA-48) enzyme producing isolates of K. pneumoniae (CDC, 2010). 
These isolates are capable of hydrolyzing a broad spectrum of β-lactam antibiotics including penicillins, cephalosporins, 
carbapenems and monobactam. Failure to identify individuals colonized with these organisms, difficulty with inoculum 
preparation, and problems intrinsic to automated systems are some of the reasons associated with this rise (Quale J, 2008). Data 
on healthcare-associated infections reported to the Centers for Diseases Control and Prevention (CDC) from 2007 indicated that 
8% of all Klebsiella isolates were carbapenem resistant as compared to a previous report of <1% in 2000 (Srinivasan and Patel, 
2008) barely 7 years earlier. This enzyme has recently been isolated in Pseudomonas (Villegas et al., 2007) and Acinetobacter 
(Robledo et al., 2010), organisms outside the Enterobacteriacae family. The mechanisms by which these multi-drug resistant gram 
negatives spread despite effective infection control measures remains to be elucidated (Quale J 2008).  
We describe the case of a 60-year-old Saudi lady with diabetes and other multiple co-morbidities who developed 
recurrent infections with multiple organisms during a prolonged stay in the intensive care unit (ICU). Being the first report of 
infection with this organism from our institution, we have tried to explore the patient’s journey to pan-drug resistance and also 
briefly reviewed the literature.    
 
Case report  
 
The patient is a 60-year-old Saudi female with type II diabetes mellitus, hypertension, pituitary adenoma, 
hypothyroidism, obesity and obstructive sleep apnea. She was in the ICU for one year. During this period she was connected to 
the ventilator that proved difficult to wean. Her hospital stay was complicated by anoxic brain damage which she sustained after 
cardiopulmonary arrest. She was previously admitted via the emergency room with productive cough, fever and shortness of 
breath that subsequently required intubation and ICU admission.   
Subsequent examination revealed bilateral pneumonia. Arterial blood gases showed a pH of 7.20; PCO2: 80mmHg; 
PO2: 66mmHg. White Blood Count was 12.4 x 109/L, hemoglobin: 12.4g/dl; and Platelet count: 203 x 109/L. Chest radiography 
Garbati et al., Afr. J. Infect. Dis. (2013) 7(1): 8 – 10 
http://dx.doi.org/10.4314/ajid.v7i1.2 
 
9
showed cardiomegaly with bilateral non-homogenous infiltrates. The admission diagnosis of community acquired pneumonia 
(CAP) with type II respiratory failure was made. The subject had a long ICU stay connected to a ventilator, had undergone several 
invasive procedures, and received immunosuppressive medications. Additionally, the patient was previously exposed to 
antibiotics belonging to nearly all classes (Penicillins, Carbapenems, Cephalosporins, Aminoglycosides, Glycopeptides, 
Glycylcyclines, Quinolones, and Polymyxins) due to infections caused by agents raging from sensitive Pseudomonas, E. coli to 
multi-drug resistant (MDR) Acinetobacter baumanii and extended-spectrum ß-lactamases (ESBLs) Klebsiella pneumoniae before 
she acquired the infection under review. 
About six months after her admission, she developed a new fever (38.9oC,) with hypotension requiring inotropic support 
and high ventilator settings. Blood culture yielded pan-drug resistant Klebsiella pneumoniae (resistant to all tested antibiotics 
from all classes) and multi-drug resistant Pseudomonas aeruginosa (sensitive only to colistin and amikacin) at 12 hours of 
incubation in both aerobic and anaerobic vials. The Klebsiella pneumoniae isolate was not tested for colistin susceptibility but was 
confirmed as a carbapenemase producer by the modified Hodge test. No further characterization of the isolate was made. At the 
same time culture of aspirate from the trachea also yielded Pseudomonas aeruginosa that was sensitive only to colistin and 
amikacin. This patient was treated successfully with a combination of colistin and amikacin with complete resolution of both the 
pneumonia and bacteremia. Repeat blood culture 48 hours into her treatment with this combination was negative.  
The patient was admitted in to a single room, under standard precautions applied, due to earlier infection with an ESBL 
organism. She remained isolated until her later transfer to a long term care facility for continuum of care. 
 
 
Discussion  
 
Infection with multi-drug resistant gram negative bacilli has been associated with significant morbidity and mortality 
(Patel et al., 2008). Bacterial isolates harboring carbapenemases are capable of hydrolyzing a broad spectrum of β-lactams 
including penicillins, cephalosporins, carbapenems and monobactam. Majority of these organisms belong to the ESCAPE 
(Enterococcus faecium, Staphylococcus aureus, Clostridium difficille, Acinetobacter baumannii, Pseudomonas aeruginosa, and 
Enterobacteriacae species) group of bacteria and are responsible for the majority of hospital- and community-acquired infections 
(Peterson, 2009). They tend to “escape” eradication by all currently available antimicrobial agents. This was highlighted in a 
recent review "bad bugs no drugs" from the Infectious Diseases Society of America (IDSA) (Boucher et al., 2009). This has 
become more worrisome especially at a time when no promising new antimicrobial agents are on the horizon (Talbot et al., 2006). 
A major risk factor for this rise is the increased use of carbapenems to treat extended-spectrum beta lactamase- (ESBL-) 
producing organisms with subsequent development of resistance to these agents (Yigit et al., 2001).   
The rising number of immunocompromised patients has further led to the increased rate of infections with these highly 
resistant organisms (Chopra et al., 2008). Receipt of antibiotics containing the oxyimino group (cefuroxime, ceftriaxone, 
cefotaxime, ceftazidime, or aztreonam) is a well known risk factor for ESBL acquisition (Paterson et al., 2004). The optimal 
treatment of Carbapenemase-producing Klebsiella pneumoniae -producing organisms is yet unknown.  With few new 
antimicrobials under development, clinicians have resorted to using older previously discarded antimicrobials, such as colistin and 
tigecycline to treat these infections (Urban et al., 2008). This approach has recently led to the emergence of organisms with 
resistance to antibiotics from all known classes, including the polymyxins (Zarkotou et al., 2010) with its attendant toxicities. 
tigecycline, which is bacteriostatic, is a glycylcycline with expanded activity against many enterobacteriaceae, including ESBLs 
and Klebsiella pneumoniae carbapenemases (KPCs). However, its low serum levels warrant caution when using it to treat 
bacteremic infections. The major concerns with colistin therapy are nephrotoxicity and neurotoxicity. Neurotoxicity might be 
difficult to ascertain especially in critically ill patients unable to report paraesthesia. 
Carbapenemase-producing Klebsiella pneumoniae has been successfully treated with single or combination 
antimicrobial agents. A recent chart review by Neuner et al (Neuner et al., 2011) reported variable susceptibilities in vitro to 
tigecycline (98%), colistin (86%), amikacin (45%) and gentamicin (22%) among 60 patients with carbapenemase-producing 
Klebsiella pneumoniae bloodstream infections. Left with no other option clinicians have been forced to use alternative antibiotics 
such as tigecycline and the polymyxins (polymyxin B or colistin) to treat infections caused by carbapenemase resistant 
Enterobacteriacae as was in this case. The 10 by 20 initiative of the IDSA that aims to develop 10 new effective antibiotics by the 
year 2020 is a laudable program that is anticipated to provide effective alternatives (IDSA, 2010). 
 
 
Conclusion 
 
Klebsiella pneumoniae isolates resistant to all commonly used antimicrobial agents have been recognized as emerging 
infectious agents of clinical significance. The global spread of this agent is challenging for clinicians with very few therapeutic 
options left for countering these pathogens. Moreover, better methods are needed for isolating these pathogens and for screening 
individuals whom they colonize while we await the discovery of new active agents against resistant Gram-negative bacteria. The 
dearth of novel antibacterial drugs in the pipeline would mean that we must conserve the efficacy of existing antibacterial drugs as 
much as possible. While these needs are being addressed, it is also critical to have protocols in place for antimicrobial 
stewardship, enhance surveillance and institute effective infection control efforts to limit the spread of these pathogens. We share 
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this case to highlight some troubling issues that soon may be relevant to increasing numbers of physicians and patients around the 
world. 
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